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BACKGROUND AND AIMS: Drugs used to treat patients with ulcerative colitis (UC) 
are not always effective because of non-specific distribution, metabolism in 
gastrointestinal tract, and side effects. We designed a nitroxide radical-containing 
nanoparticle (RNPO) that accumulates specifically in the colon to suppress 
inflammation and reduce the undesirable side effects of nitroxide radicals. 
METHODS: RNPO was synthesized by assembly of an amphiphilic block copolymer 
that contains stable nitroxide radicals in an ether-linked hydrophobic side chain. 
Biodistribution of RNPO in mice was determined from radioisotope and electron spin 
resonance measurements. The effects of RNPO were determined in mice with dextran 
sodium sulfate (DSS)-induced colitis and compared with those of low-molecular-weight 
drugs (4-hydroxyl-2,2,6,6-tetramethylpiperidine-1-oxyl [TEMPOL] or mesalamine). 
RESULTS: RNPO, with a diameter of 40 nm and a shell of poly(ethylene glycol), had a 
significantly greater level of accumulation in the colonic mucosa than 
low-molecular-weight TEMPOL or polystyrene latex particles. RNPO was not absorbed 
into the bloodstream through the intestinal wall, despite its long-term retention in the 
colon, which prevented its distribution to other parts of the body. Mice with 
DSS-induced colitis had significantly lower disease activity index and less 
inflammation following 7 days of oral administration of RNPO, compared with 
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DSS-induced colitis mice or mice given low-molecular-weight TEMPOL or 
mesalamine. 
CONCLUSION: We designed an orally administered RNPO that accumulates 
specifically in the colons of mice with colitis and is more effective in reducing 
inflammation than low-molecular-weight TEMPOL or mesalamine. RNPO might be 
developed for treatment of patients with UC. 
Key words: Nitroxide Radical-containing Nanoparticles; Inflammatory Bowel Disease; 
Reactive Oxygen Species; Nanotherapy. 
 
Abbreviation used in this paper: AUC, area under the concentration-time curve; CD, 
Crohn’s disease; CMS, chloromethylstyrene; DAI, disease activity index; DHE 
dihydroethidium; DSS, dextran sodium sulfate; ESR, electron spin resonance; IBD, 
inflammatory bowel disease; IL, interleukin; H&E,  hematoxylin and eosin; GIT, 
gastrointestinal tract; MeO-PEG-b-PCMS, methoxy-poly(ethylene 
glycol)-b-poly(chloromethylstyrene); MeO-PEG-b-PMOT, methoxy-poly(ethylene 
glycol)-b-poly[p-4-(2,2,6,6-tetramethylpiperidine-1-oxyl)oxymethylstyrene]; 
MeO-PEG-SH, methoxy-poly(ethylene glycol)-sulfanyl; MPO, myeloperoxidase; PEG, 
poly(ethylene glycol); PEG-b-PMNT, poly(ethylene 
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glycol)-b-poly[p-4-(2,2,6,6-tetramethylpiperidine-1-oxyl)aminomethylstyrene]; RNPN, 
nitroxide radical-containing nanoparticles prepared by PEG-b-PMNT; RNPO, nitroxide 
radical-containing nanoparticles prepared by MeO-PEG-b-PMOT; TEMPOL, 
4-hydroxyl-2,2,6,6-tetramethylpiperidine-1-oxyl; UC, ulcerative colitis. 
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Inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative 
colitis (UC), affects millions of patients worldwide. 1 – 4  Since the etiology and 
pathogenesis of IBD are not well understood, it is considered an intractable disease. The 
intestinal mucosa of patients with IBD is characterized by reactive oxygen species 
(ROS) overproduction and an imbalance of important antioxidants, leading to oxidative 
damage. Self-sustaining cycles of oxidant production may amplify inflammation and 
mucosal injury.5– 8 In several experimental models, antioxidant compounds and free 
radical scavengers have improved colitis. 9– 11
Nanoparticles such as liposome and polymeric micelles have gained 
worldwide attention as a new medical technology, because they change biodistribution 
of drugs to result in therapeutic effect of drugs significantly.
 However, these compounds are not 
completely effective due to a non-specific drug distribution, a low retention in the colon 
and side effects. If antioxidant compounds are specifically targeted to the diseased sites 
and effectively scavenge excessive generated ROS, they represent a safe and effective 
treatment for IBD. 
12,13 In particular, the 
intratumoral microdistribution of nanoparticle has been studied for over two decades 
that nanoparticles can accumulate in sites of tumor due to the increased vascular 
permeability. 14 – 17 Recently, we have developed an amphiphilic block copolymer, 
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poly(ethylene 
glycol)-b-poly[p-4-(2,2,6,6-tetramethylpiperidine-1-oxyl)aminomethylstyrene] 
(PEG-b-PMNT), possessing stable nitroxide radicals in the hydrophobic segment as a 
side chain via an amine linkage, which forms core-shell-type micelles in the 
physiological environment with an average diameter of about 40 nm, and termed 
nitroxide radical-containing nanoparticle (RNPN).18 Nitroxide radicals are confined in 
the core of this micelle, which shows high biocompatibility, including long-term blood 
circulation when administered intravenously and low toxicity. Therefore, RNPN has 
been studied for therapy in oxidative stress injuries18 – 22 and bioimaging.23,24
In this study, we describe a novel nanotherapy for the treatment of UC via oral 
administration. In order to target the nanoparticle to the colon area, its accumulation in 
the colonic mucosa is optimized, preventing its uptake into the bloodstream. We 
designed a new redox polymer, methoxy-poly(ethylene 
glycol)-b-poly[p-4-(2,2,6,6-tetramethylpiperidine-1-oxyl)oxymethylstyrene] 
 For 
example, pH-sensitive RNPN works effectively in acute renal injury18 and cerebral 
ischemia-reperfusion19 because it disintegrates in acidic conditions of diseased area by 
protonation of amino groups. However, pH-disintegrative character is not suitable for 
the treatment of UC via oral administration.  
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(MeO-PEG-b-PMOT), which is an amphiphilic block copolymer with stable nitroxide 
radicals in a hydrophobic segment as a side chain via an ether linkage and forms 
40-nm-diameter core-shell-type micelles (RNPO) by self-assembly in the aqueous 
environments regardless of pH (Figure 1A). Here, we investigate specific accumulation 
of RNPO in colon after oral administration by comparison to low-molecular-weight 
compound, 4-hydroxyl-2,2,6,6-tetramethylpiperidine-1-oxyl (TEMPOL) and 
commercial available polystyrene latex particles with different sizes from 40 nm to 1 
µm. Also, we examine the therapeutic effect of RNPO on dextran sodium sulfate 
(DSS)-induced colitis model in mice, compared to low-molecular-weight TEMPOL and 
mesalamine, a commercial anti-ulcer drug. Our results show that RNPO significantly 
accumulates in colonic mucosa area, especially inflammatory sites, without absorption 
into bloodstream and has an extremely high therapeutic efficiency in mice with 
DSS-induced colitis (Figure 1B).  
 
Materials and Methods 
Preparation of RNPO  
RNPO was prepared by a self-assembling MeO-PEG-b-PMOT block 
copolymer, as previously reported.18 Briefly, methoxy-poly(ethylene 
9 
 
glycol)-b-poly(chloromethylstyrene) (MeO-PEG-b-PCMS) was synthesized by the 
radical telomerization of chloromethylstyrene (CMS) using methoxy-poly(ethylene 
glycol)-sulphanyl (MeO-PEG-SH; Mn = 5,000) as a telogen. The chloromethyl groups 
were converted to TEMPOs via a Williamson ether synthesis of benzyl chloride in the 
MeO-PEG-b-PCMS block copolymer with the alkoxide of TEMPOL, as previously 
reported. RNPO was prepared from MeO-PEG-b-PMOT by dialysis method; Micelle 
without nitroxide radicals was similarly prepared from MeO-PEG-b-PCMS as a control 
and termed “micelle”. 
 
Preparation of rhodamine-labeled RNPO, 125I-labeled RNPO, polystyrene latex 
particles with nitroxide radicals 
Detailed methods were described in Supplementary Materials and Methods 
section. 
 
Animals 
All experiments were carried out using 7-week-old male ICR mice (32–35 g) 
purchased from Charles River Japan, Inc. Mice were maintained in the experimental 
animal facilities at the University of Tsukuba. All experiments were performed 
according to the Guide for the Care and Use of Laboratory Animals at the University of 
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Tsukuba. 
 
Localization of RNPO in the colon 
Localization of RNPO in the colon was determined by fluorescent 
rhodamine-labeled RNPO. Rhodamine-labeled RNPO was prepared via thiourethane 
bond between MeO-PEG-b-PMOT possessing reduced TEMPO moieties and 
rhodamine B isothiocyanatein (see Supplementary Materials and Methods). Mice were 
killed 4 hours after oral administration of 1 mL of rhodamine-labeled RNPO (5 mg/mL). 
Residues in the colon were gently removed with phosphate buffered saline (50 mM, pH 
7.4), and 7-μm thick colon sections were prepared. Localization of rhodamine-labeled 
RNPO was recorded using a fluorescent microscope. 
 
Accumulation of RNPO in the colon 
Accumulation of RNPO was determined by ESR assay. One mL of 
low-molecular-weight TEMPOL, RNPO and different sized polystyrene latex particles 
with an equivalent nitroxide concentration (1.33 mg; 7.5 μM) were orally administered 
to mice. Mice were killed 1, 4, 12, 24, and 48 hours after oral administration. Whole 
colons were homogenized in 1 mL of phosphate buffered saline (50 mM, pH 7.4) 
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containing potassium ferricyanide (50 mM). The ESR signal intensities in homogenized 
samples were measured by an X-band ESR spectrometer (JES-TE25X, JEOL, Tokyo, 
Japan) at room temperature. The amount of nitroxide radicals in the colon was 
determined by ESR measurements under the following conditions: frequency, 9.41 
GHz; power, 10.00 mW; center field, 333.3; sweep width, 5 mT; sweep time, 0.5 min; 
modulation, 0.1 mT; time constant, 0.1 s. 
 
Biodistribution of RNPO 
125I-labebled RNPO was prepared via reaction between RNPO and Na[125I] with 
present of chloramine-T as a catalyst (see Supplementary Materials and Methods). Mice 
were fasted for 1 day before the experiment and 0.5 mL of 125I-labeled RNPO (20 
mg/mL) was orally administered. Then, mice were sacrificed at 0.25, 0.5, 1, 2, 4, 8, 12, 
and 24 hours after oral administration. The major digestive organs (small intestine, 
cecum, and colon) and blood were isolated, and their radioactivities were measured by 
a γ-counter (ARC-380, Aloka, Japan). The percentage of radioactivity in each organ 
was determined based on the initial total radioactivity. 
 
Induction of colitis by DSS and drug administration 
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Colitis in mice was induced by 3% (wt/vol) DSS (5,000 daltons; Wako Pure 
Chemicals) supplemented in the drinking water for 7 days. The experiment was 
designed to six groups: normal control group, DSS-injured group, 
low-molecular-weight TEMPOL-treated group, micelle-treated group, RNPO-treated 
group and mesalamine-treated group. The equivalent doses of drugs (0.2 mM/kg) were 
orally administered daily during the 7 days of DSS treatment. The concentrations of 
low-molecular-weight TEMPOL, micelle and RNPO were adjusted in distilled water, 
and the solutions were filtered with a 0.25-μm cellulose acetate filter. Mesalamine was 
suspended in 0.5% (wt/vol) carboxymethyl cellulose. 
 
Evaluation of colitis severity by disease activity index (DAI) and colon length; 
Histological assessment; Measurements of myeloperoxidase (MPO) activity, 
interleukin (IL)-1 β and superoxide production 
Detailed methods were described in Supplementary Materials and Methods 
section. 
 
Intravital observation by in vivo live imaging 
Aqueous solution of DSS (3% wt/vol) was administered by free access for 7 
days to induce colitis in mice. One mL of RNPO (10 mg/mL) was orally administered 
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daily. After 7 days of treatment, mice were anesthetized with urethane (15 g/kg, 
Sigma-Aldrich) and an arc-shaped incision was made in the peritoneum to expose the 
colon. Then, approximately 1 cm length incision was made to observe the colonic 
mucosa and the remained contents in the colon were removed gently by physiological 
saline. Mice were set on the stage of microscope and in vivo live imaging was acquired 
after 2 hours with a microscope. Dead cells in colonic mucosa were identified by 
staining of propidium iodide in physiological buffer (50 μg/mL; Wako Pure Chemicals) 
under an excitation wavelength of 488 nm and an emission wavelength of 515 nm.  
 
Survival rate experiment  
The survival rate of mice was determined by replacing drinking water with a 
3% (wt/vol) solution of DSS for 15 days. Starting on day 5, drugs were oral 
administered daily until day 15, and the number of surviving mice was counted until 
day 15. 
 
Statistical analysis 
All values are expressed as mean ± standard error of mean (SEM). Differences 
between groups were examined for statistical significance using the one-way and 
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two-way ANOVA, followed by Bonferroni post-hoc test (SPSS software, IBM Corp., 
NY, USA). A P-value < .05 was considered significant for all statistical analyses. 
 
Results 
Specific accumulation of RNPO in colonic mucosa and inflamed colon area 
The accumulation of nanoparticles in the colon area is one of the most important 
features for an effective nanomedicine against UC. Firstly, we orally administered 
fluorescently labeled nanoparticles, and analyzed the accumulation of these 
nanoparticles in the colon by fluorescent microscopy. Here, we prepared 
rhodamine-labeled RNPO (see Supplementary Materials and Methods). After oral 
administration of rhodamine-labeled RNPO, there was a strong fluorescent signal at the 
colonic mucosa area, as compared to oral administration of low-molecular-weight 
fluorescein (Figure 2A). This result indicates effective accumulation of RNPO in the 
colonic mucosa. 
In order to quantify the accumulation of nanoparticles in the colon area, we 
compared RNPO with different sizes of commercial available polystyrene latex particles 
and low-molecular-weight compound, TEMPOL. Because we introduced nitroxide 
radicals into the particles, their accumulation could be quantitatively monitored by 
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electron spin resonance (ESR) measurements. When we orally administered 
low-molecular-weight TEMPOL to mice, almost no ESR signal was observed in the 
colon, as shown in Figure 2B. In contrast, polystyrene latex particles showed a higher 
accumulation in the colon compared to low-molecular-weight TEMPOL. From these 
results, the size-dependent accumulation in colon was observed. Polystyrene latex 
particles with 40 nm and 100 nm in size accumulated higher than large-sized particles 
(0.5 µm and 1 µm), which is consistent with previous reports.25,26
Next, we investigated the specific accumulation of RNPO in the injured colon. 
 Interestingly, when 
RNPO was administrated orally to mice, considerable high accumulation of RNPO in 
colon was observed, as compared to polystyrene latex particles, even though the same 
size (40 nm). The area under the concentration-time curve (AUC), an important 
parameter in biopharmaceuticals and pharmacokinetics, of RNPO was 1223.3, which 
was significantly higher than 27.8 of low-molecular-weight TEMPOL. The AUC of 
polystyrene latex particles with sizes 40 nm, 100 nm, 0.5 µm and 1 µm were 249.5, 
204.7, 83.7 and 32.9, respectively. High colloidal stability of RNPO due to the PEG 
tethered chains on the surface might be effective to accumulate in colonic mucosa as 
compared to polystyrene latex particles. The extremely high accumulation of RNPO in 
colonic mucosa can be anticipated for high performance efficiency as a colitis therapy. 
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Aqueous solution of DSS (3% wt/vol) was administered by free access to induce colitis 
in mice. We orally administered RNPO at day 5 and quantified the amount of RNPO in 
the colon by ESR measurements 4 hours after administration. Interestingly, the amount 
of accumulated RNPO in the colon of DSS-injured mice was 50% higher than that in the 
normal colon under the same administration conditions (1.57 ± 0.18 μg/cm of colon 
length for DSS-treated mice and 1.01 ± 0.13 μg/cm of colon length for normal mice) 
(Figure 2C). This result suggested that RNPO accumulates to a greater extent in 
inflammatory sites, such as in UC.  
 
Distribution and non-absorption into bloodstream of RNPO after oral administration 
As previously mentioned, we confirmed the specific accumulation of RNPO in 
the DSS-injured colon. It is also important to estimate the non-specific distribution in 
whole body. Therefore, to precisely evaluate non-specific distribution, we used 
radioisotope 125I-labeled RNPO (see Supplementary Materials and Methods), which 
moved from the small intestine, to the cecum, and to the colon over time after oral 
administration (Figure 3A). Specifically, in the first hour after administration, 3.2% of 
the initial dose of RNPO had reached the colon. It accumulated to a maximum of 14.5% 
of the initial dose 4 hours after administration. Twenty-four hours after administration, 
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there was 0.5% of the initial dose of RNPO remaining in the colon. Importantly, we did 
not observe the uptake of RNPO into the bloodstream (Figure 3A). This is in sharp 
contrast to low-molecular-weight compounds, such as TEMPOL. This difference in 
bloodstream uptake via the gastrointestinal tract (GIT) was further confirmed by ESR 
measurements. Low-molecular-weight TEMPOL was absorbed into the bloodstream 
through the GIT in normal mice and even more in DSS-treated mice (Figure 3B). 
However, when RNPO was administered orally, there was no observable ESR signal in 
the blood, which was consistent with the results from the experiments of 125I-labeled 
RNPO. In the present study, oral nanotherapy with RNPO prevented uptake into the 
bloodstream, suggesting a lack of systemic side effects. 
 
Stability of RNPO in GIT 
Next, we evaluated the stability of orally administered RNPO in the GIT using 
ESR spectra of RNPO in the colon. The ESR signals of low-molecular-weight TEMPOL 
in the colon showed a sharp triplet due to an interaction between the 14N nuclei and the 
unpaired electron, as previously reported18 (Figure 3B, inset, grey spectrum). In contrast, 
the ESR signals of RNPO in the colon were broad (Figure 3B, inset, black spectrum), 
suggesting that RNPO remains as core-shell type micelle even in the GIT. The stability 
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of self-assembled RNPO with several tens of nanometers in GIT could prevent the 
uptake into the bloodstream through the intestinal wall. After reaching colon, RNPO is 
accumulated in inflamed and mucosal area, followed by effectively scavenging ROS. It 
is noted that RNPN, which contains amino group as side chains in the hydrophobic 
segment, is absorbed into the bloodstream when administered orally (data not shown). 
It is likely that the disintegration of RNPN in the stomach facilitates its uptake into the 
bloodstream through the intestinal wall, which was not observed in RNPO.  
 
Therapeutic effect of RNPO on DSS-induced colitis in mice 
Since orally administered RNPO accumulated in the colonic mucosa of 
DSS-injured mice and was not absorbed into the bloodstream, it is anticipated to be an 
ideal nanomedicine for UC treatment. Therefore, we investigated its therapeutic and 
suppressive effects on DSS-induced colitis model in mice. RNPO was orally 
administered daily to DSS-injured mice for 7 days. Additional DSS-injured mice were 
treated with low-molecular-weight TEMPOL, commercially anti-ulcer mesalamine and 
micelle without nitroxide radicals as controls. After 7 days of treatment, we assessed 
the severity of colitis on the basis of DAI27 (see Supplementary Table 1), colon length, 
and histological analysis. Mice treated with DSS had a significant increase in DAI and 
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shortening of the colon compared to control mice (Figure 4A,B). The treatments with 
low-molecular-weight TEMPOL or mesalamine showed efficiency to decrease DAI as 
compared to DSS-treated mice, though this efficiency was not significant. On the 
contrary, RNPO-treated mice showed much lower DAI and preserved colon length 
compared to DSS-treated mice (P < .01) and other low-molecular-weight drugs-treated 
mice. It should be noted that no effect was observed when polymeric micelle without 
nitroxide radicals was administered instead of RNPO. Additionally, histological analyses 
showed that mucosal structures of DSS- and micelle-treated mice were significantly 
damaged, viz., destruction of crypts and high levels of neutrophil invasion were 
observed in these mice. Low-molecular-weight TEMPOL- or mesalamine-treated mice 
showed moderately damaged mucosal structures. Contrary of those treatments, 
RNPO-treated mice showed almost similar to that of control mice (Figure 4C), 
indicating the significant therapeutic effect of RNPO on DSS-induced colitis in mice.  
We then analyzed ability of RNPO to suppress systemic inflammation in 
DSS-induced colitis. Hematological analyses were performed to reveal the massive 
infiltration of leukocytes. Blood from RNPO-treated mice had a significant lower level 
of white blood cells compared to DSS- and micelle-treated mice (P < .05), indicating 
lower levels of neutrophil invasion in RNPO-treated mice (Figure 5A). 
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Low-molecular-weight TEMPOL and mesalamine showed the effect to suppress white 
blood cells in DSS-treated mice; however, the significance was not observed. 
Furthermore, results of the hematological analysis indicated higher levels of red blood 
cells and hemoglobin in the blood of RNPO-treated mice (Figure 5B,C). This suggests 
that the intestinal wall was protected from hemorrhage in RNPO-treated mice. We 
further investigated the desquamation of impaired epithelial cells and cell death in 
colonic mucosa by intravital observation using in vivo microscopic live imaging and 
propidium iodide staining.28
 
 The results showed that a great number of desquamated 
cells and cell death existed in colonic mucosa of DSS-treated mice (Figure 5D, 
Supplementary Video 1). In contrast, in colonic mucosa of RNPO-treated mice, the 
desquamation and cell death was remarkably suppressed. On the basis of these results, 
it was confirmed that the colonic injury is protected by the oral administration of RNPO. 
RNPO suppresses pro-inflammatory mediators and enhances survival rate in mice 
In addition, after 7 days of treatment, we determined pro-inflammatory mediators 
in the colonic mucosa, including MPO activity, IL-1β and superoxide. These 
pro-inflammatory mediators are well-known markers of inflammation and play an 
important role in UC. Low-molecular-weight TEMPOL and mesalamine did not 
effectively suppress these pro-inflammatory mediators induced by DSS (Figure 6A–C). 
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On the other hand, RNPO-treated mice showed a significant suppression of 
pro-inflammatory mediators in colonic tissue (P < .01). It should be noted that no 
therapeutic effect was observed for polymeric micelle without nitroxide groups, 
indicating that effective delivery of nitroxide groups in colonic mucosa area is one of 
the most important factors for UC treatment. Because low-molecular-weight drugs tend 
to be absorbed into the bloodstream via mesentery, sufficient dose of drugs might not 
reach to target area to result in low therapeutic efficacy. Side effects in whole body 
should also be considered such kind of low-molecular weight drugs. Finally, we 
investigated the effect of orally administered RNPO on the survival rate of mice with 
colitis induced by 5-day administration of DSS. After 15 days of treatment, orally 
administered low-molecular-weight TEMPOL and mesalamine slightly increased the 
survival rate (33.3% and 50%, respectively) compared with DSS- and micelle-treated 
mice (16.7%) (Figure 6D). On the other hand, RNPO treatment significantly increased 
the survival rate of DSS-treated mice to 83.3%. This indicates that RNPO has not only 
suppressive but also therapeutic effects on mice with DSS-induced colitis.  
 
Discussion 
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Despite significant advances in treatments, IBD remains a major clinical problem, 
because no drug is entirely effective. For many years, there were only 2 treatment 
options for IBD: corticosteroids and mesalamine.29,30 Although they are effective in 
treating IBD in some extent, their severe side effects have raised significant concerns 
among both physicians and patients, and limited their use. In addition, anti-TNF-α 
antibody is employed to suppress inflammation of UC, which works well though it is 
cost-oriented therapy with multiple side effects. 31  Recently, many promising 
low-molecular-weight medications, such as antioxidants, have been found beneficial in 
experimental models of UC.9–11,32 Unfortunately, results of clinical trials investigating 
these promising drugs have been largely negative. The drawbacks of current 
low-molecular-weight drugs are poor stability in stomach, low solubility and side 
effects on whole body when they enter the bloodstream. In this study, we have 
developed a novel nitroxide radical-containing nanoparticle RNPO that accumulates 
specifically in colon area to suppress the inflammation in DSS-induced colitis mice. For 
UC treatment via oral administration, this nanoparticle showed excellent properties, 
including high accumulation in inflamed tissues of colon and non-absorption into the 
bloodstream.  
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Here, we found that the accumulation in colon area depends on the sizes and 
PEGylated character of particles. Both low-molecular-weight drugs, submicron- and 
micron-sized polystyrene latex particles showed poor accumulation in colon, whereas 
higher accumulation of particles with approximately several tens of nanometers was 
observed. Optimal size of several tens of nanometers allowed easier diffusion in the 
mucosa compared to larger sized particles.25,26,33 In addition, 40-nm-diameter RNPO 
with PEG shell showed significantly high accumulation and long retention in colon area 
compared to polystyrene latex particles with similar size of 40 nm. PEGylated character 
of RNPO might protect nitroxide radicals in the hydrophobic core from hash conditions 
of GIT after oral administration, resulting in the significant accumulation in colon 
area.34 Furthermore, PEG chains of RNPO may achieve mucoadhesion due to their 
ability to inter-diffuse among the mucus network and polymer entanglement with 
mucin, which is composed of glycoprotein.35 Therefore, PEGylated character of RNPO 
showed much significant effect on its accumulation in colonic mucosa. Eventually, we 
observed the accumulation of RNPO in colon is almost 50 times higher than that of 
low-molecular-weight TEMPOL. To deliver sufficient dose of anti-inflammatory drugs 
for UC treatment, high dose of drugs is required, however it leads to undesirable side 
effects, because almost all low-molecular-weight drugs tend to metabolize in upper GIT 
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or absorb into bloodstream.36,37 In case of RNPO, no absorption into bloodstream was 
observed via oral administration route, which improves accumulation in colon region 
and prevents side effects to whole body. Another interesting phenomenon in our study 
is the higher accumulation of nanoparticles in inflammatory colon than healthy colon. 
Mucus layer in colon area is significantly thicker than that in small intestine, which is 
considered as a significant barrier to nanoparticle penetration.38 In colon of patients 
with UC, the overall thickness of the adherent mucus layer is reduced due to the 
reduction of goblet cells,38,39 resulting in the facile penetration of nanoparticles in 
inflammatory tissues. In addition, the opening tight junction of epithelium cells in UC 
is another explanation for higher accumulation of nanoparticles.40
After investigating the distribution of RNPO in GIT, we used DSS-induced colitis 
model mice to compare suppressive effect of RNPO with low-molecular-weight 
TEMPOL and mesalamine, a commercial medication for UC treatment. Our results 
showed that low-molecular-weight TEMPOL and mesalamine did not clearly show 
their effects, whereas RNPO effectively reduced the severity of colitis by suppression of 
DAI and damage of colonic architecture. It is noted that micelle without nitroxide 
radicals did not show any therapeutic effect at all on colitis mice, indicating that ROS 
 It should be noted 
that no absorption of RNPO into bloodstream was observed even in colitis mice.   
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scavenging character of nitroxide radicals plays critical role in the effect of RNPO on 
colitis mice. Further investigations, it is confirmed that RNPO did not simulate the 
whole body immune system as well as effectively suppressed pro-inflammatory 
mediators such as MPO, IL-1β and superoxide. The therapeutic efficiency of RNPO was 
further confirmed by survival data, which showed higher survival rate of RNPO-treated 
mice compared to low-molecular-weight TEMPOL- or mesalamine-treated mice.  
In conclusion, we have developed a novel nitroxide radical-containing 
nanoparticle, RNPO, which possesses anti-oxidative nitroxide radicals in the core for 
treatment of DSS-induced colitis mice. RNPO significantly accumulated not only in the 
mucosa but also higher in inflammatory sites of the colon, resulting in a high 
therapeutic effect, which was not observed in low-molecular-weight drugs. In addition, 
RNPO may lack the undesirable side effects of low-molecular-weight TEMPOL, since it 
is not absorbed into the bloodstream. Our results indicated that the therapeutic 
efficiency of nitroxide radicals could be successfully enhanced by using nanoparticles 
to suppress inflammation in the colon area and reduce undesirable side effects. 
Therefore, we believe that RNPO may become an important therapeutic agent for the 
treatment of UC. 
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Figure Legends: 
Figure 1. Schematic illustration of RNPO and nanotherapy for DSS-induced colitis in 
mice. (A) RNPO is prepared by self-assembly of a poly(ethylene 
glycol)-b-poly(4-methylstyrene) block copolymer possessing nitroxide radical TEMPO 
moieties. (B) After oral administration, low-molecular-weight drugs, such as TEMPOL, 
are degraded and absorbed into the bloodstream in stomach and small intestine before 
reaching the colon. In contrast, RNPO is stable and withstands the harsh conditions of 
the gastrointestinal tract (GIT), and reach the colon to scavenge ROS, especially sites of 
inflammation. 
 
Figure 2. Specific accumulation of RNPO in mice with colitis. (A) Localization of 
RNPO in the colon was determined with rhodamine-labeled RNPO. Mice were sacrificed 
4 hours after oral administration of 1 mL of rhodamine-labeled RNPO at a dose of 5 
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mg/mL (n = 3), and colon sections were prepared. Localization of rhodamine-labeled 
RNPO in the colon was analyzed by fluorescent microscopy. Scale bars, 200 μm. (B) 
Accumulation of low-molecular-weight TEMPOL, RNPO and polystyrene latex 
particles in the colon. After oral administration of low-molecular-weight TEMPOL, 
RNPO and polystyrene latex particles with equivalent nitroxide radicals (1.33 mg; 7.5 
μM), the amount of nitroxide radicals was measured by ESR. The data are expressed as 
mean ± SEM, n = 3. (C) Specific accumulation of RNPO in the inflamed colon. Colitis 
was induced in mice by supplementing the drinking water with DSS (3% wt/vol) for 5 
days. The amount of nitroxide radicals in the normal colon and the inflamed colon was 
determined by ESR measurement 4 hours after administration of RNPO. The data are 
expressed as mean ± SEM, n = 3. 
 
Figure 3. Biodistribution of RNPO in GIT and bloodstream. (A) The biodistribution of 
RNPO was determined using 125I-labeled RNPO. The percentages of radioactivity in 
each organ and in the blood were determined by comparison to the initial total 
radioactivity. The data are expressed as mean ± SEM, n = 5. (B) Absorption of 
low-molecular-weight TEMPOL and RNPO into the bloodstream of normal mice (solid 
line) and colitis mice (dashed line). After administration of low-molecular-weight 
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TEMPOL and RNPO, the amount of nitroxide radicals in the plasma was determined by 
ESR measurement. The data are expressed as mean ± SEM, n = 3. (Inset) The ESR 
spectra of low-molecular-weight TEMPOL (grey spectrum) and RNPO (black spectrum) 
in the colon homogenate after 4 h oral administration. 
 
Figure 4. Therapeutic effect of RNPO on DSS-induced colitis in mice. (A) Changes in 
disease activity index. Disease activity index is the summation of the stool consistency 
index (0–3), fecal bleeding index (0–3), and weight loss index (0–4). The data are 
expressed as mean ± SEM, *P < .05, **P < .01 and ***P < .001 vs. control group; ‡P 
< .05 and ¶P < .001 vs. DSS groups, n = 6–7, two-way ANOVA, followed by 
Bonferroni post-hoc test. (B) Preservation of colon length. After 7 days of treatment, the 
colon was collected and measured. The data are expressed as mean ± SEM, **P < .01, n 
= 6–7. (C) Protection of mucosal architecture. After 7 days of treatment, the colon was 
collected, and 7-μm-thick sections of distal colon were prepared. Sections of the distal 
colon were stained by hematoxylin and eosin (H&E), and assessed histologically. Scale 
bars, 200 μm. 
 
Figure 5. Hematological analyses in the peripheral blood and intravital observation of 
29 
 
colon. (A–C) After 7 days of treatment, blood was collected by intracardiac puncture 
with a heparin-containing syringe, and hematological analyses were performed by 
automatic hematology analyzer (Celltac α, MEK-6358; Nihon Kohden Co., Tokyo, 
Japan). Blood samples were analyzed for white blood cells (A), red blood cells (B), and 
hemoglobin (C). The data are expressed as mean ± SEM, *P < .05, **P < .01, ***P 
< .001, n = 6. (D) The desquamation of impaired epithelial cells and cell death in 
colonic mucosa were determined by in vivo microscopic live imaging and propidium 
iodide staining. The bright field images were acquired 2 hours after removing remains 
in the colon. The cell death images were recorded immediately after staining of 
propidium iodide under an excitation wavelength of 488 nm and an emission 
wavelength of 515 nm. 
 
Figure 6. RNPO reduced pro-inflammatory mediators and increased survival rate in 
colitis mice. (A–C) After 7 days of treatment, colon homogenates were prepared, and 
MPO activity, superoxide, and IL-1β were measured. (A) MPO activity was determined 
by a colorimetric assay using o-dianisidine hydrochloride and H2O2 as substrates. (B) 
Measurement of IL-1β in colon homogenate was performed with an ELISA kit for mice. 
Protein content in the colon homogenate was determined by a BCA kit. (C) Generation 
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of superoxide in colon homogenates was measured by dihydroethidium (DHE) 
fluorescence. The fluorescence intensity was measured with an excitation wavelength 
of 530 nm and an emission wavelength of 620 nm. Superoxide values were expressed 
as intensity per mg of protein, and the superoxide value of the control group was 
standardized to 100%. The data are expressed as mean ± SEM, *P < .05, **P < .01, 
***P < .001, n = 6. (D) The survival rate of mice was determined after 15 days of 3% 
(wt/vol) DSS treatment. Starting on day 5, test drugs were orally administered daily 
until day 15. The number of surviving mice was counted until day 15, n = 6. 
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